TY  - GEN
AU  - Martín-Escolano, Rubén
AU  - Fernandez-Rodriguez, Amanda
AU  - Tarancon-Diez, Laura
AU  - Berenguer, Juan
AU  - Codina Márquez, Helena
AU  - Amigot-Sánchez, Rafael
AU  - González-García, Juan
AU  - Hontañón, Víctor
AU  - Pérez-Latorre, Leire
AU  - Ibañez-Samaniego, Luis
AU  - Llop-Herrera, Elba
AU  - Olveira, Antonio
AU  - Díaz, Laura
AU  - Martinez, Isidoro
AU  - Jimenez-Sousa, Maria Angeles
AU  - Resino, Salvador
PY  - 2026
DO  - 10.3389/fimmu.2026.1683092
UR  - https://hdl.handle.net/20.500.12105/27350
AB  - Introduction: The immunological drivers of portal hypertension regression after hepatitis C virus (HCV) cure are poorly understood, particularly in the context of human immunodeficiency virus (HIV) coinfection We aimed to identify baseline immune...
LA  - eng
PB  - Frontiers Media
KW  - DAA therapy
KW  - HIV
KW  - HVPG regression
KW  - Biomarkers
KW  - Chronic hepatitis C
KW  - Immunological profile
KW  - Adult
KW  - Antiviral Agents
KW  - Biomarkers
KW  - CD4-Positive T-Lymphocytes
KW  - Coinfection
KW  - Female
KW  - HIV Infections
KW  - Hepacivirus
KW  - Hepatitis C
KW  - Hepatitis C, Chronic
KW  - Humans
KW  - Hypertension, Portal
KW  - Liver Cirrhosis
KW  - Male
KW  - Middle Aged
KW  - Prospective Studies
TI  - HIV status defines distinct immunological drivers of persistent portal hypertension after HCV cure in people with advanced cirrhosis.
TY  - research article
ER  -